Julie R. Gralow, MD of Seattle Cancer Care Alliance explains the impact of the trial on clinical practice, arguing that the data now shows the important role PARP inhibitors have in metastatic breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy
Advertisement